NLRP3 ‐directed antisense oligonucleotides reduce microglial immunoactivities in vitro
Journal of Neurochemistry · 17.03.2023
DOI: 10.1111/jnc.15778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 17.03.2023. Verfasst von Charlotte Braatz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Innate Immunity, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Microglia, NLR Family, Pyrin Domain-Containing 3 Protein, Oligonucleotides, Antisense. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alzheimer Forschung Initiative, BONFOR research commission of the medical faculty of the University of Bonn, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Alzheimer's disease (AD) is associated with the cerebral deposition of Amyloid‐β (Aβ) peptide, which leads to NLRP3 inflammasome activation and subsequent release of interleukin‐1β (IL‐1β) and interleukin‐18 (IL‐18). NLRP3 reduction has been found to increase microglial clearance, protect from synapse loss, and suppress both the changes to synaptic plasticity and spatial memory dysfunction observed in murine AD models. Here, we test whether NLRP3‐directed antisense oligonucleotides (ASOs) can be harnessed as immune modulators in primary murine microglia and human THP‐1 cells. NLRP3 mRNA degradation was achieved at 72 h of ASO treatment in primary murine microglia. Consequently, NLRP3‐directed ASOs significantly reduced the levels of cleaved caspase‐1 and mature IL‐1β when microglia were either activated by LPS and nigericin or LPS and Aβ. In human THP‐1 cells NLRP3‐targeted ASOs also significantly reduced the LPS plus nigericin‐ or LPS plus Aβ‐induced release of mature IL‐1β. Together, NLRP3‐directed ASOs can suppress NLRP3 inflammasome activity and subsequent release of IL‐1β in primary murine microglia and THP‐1 cells. ASOs may represent a new and alternative approach to modulate NLRP3 inflammasome activation in neurodegenerative diseases, in addition to attempts to inhibit the complex pharmacologically. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Innate Immunity, University of Bonn, Bonn, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
- Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
- Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
ORCID-Profile: Charlotte Braatz, Kishore Aravind Ravichandran, Matheus Garcia de Fragas, Angelika Griep, Róisín M McManus, Michael T Heneka
Förderung
- Alzheimer Forschung Initiative
- BONFOR research commission of the medical faculty of the University of Bonn
- Deutsche Forschungsgemeinschaft
- Deutscher Akademischer Austauschdienst
Zitieren
APA
Braatz, C., Komes, M. P., Ravichandran, K. A., de Fragas, M. G., Griep, A., Schwartz, S., McManus, R. M., & Heneka, M. T. (2023). NLRP3 ‐directed antisense oligonucleotides reduce microglial immunoactivities in vitro. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15778
Vancouver
Braatz C, Komes MP, Ravichandran KA, de Fragas MG, Griep A, Schwartz S, et al. NLRP3 ‐directed antisense oligonucleotides reduce microglial immunoactivities in vitro. Journal of Neurochemistry. 2023. doi:10.1111/jnc.15778
BibTeX
@article{Braatz2023,
author = {Braatz, Charlotte and Komes, Max P and Ravichandran, Kishore Aravind and de Fragas, Matheus Garcia and Griep, Angelika and Schwartz, Stephanie and McManus, Róisín M and Heneka, Michael T},
title = {NLRP3 ‐directed antisense oligonucleotides reduce microglial immunoactivities in vitro},
journal = {Journal of Neurochemistry},
year = {2023},
doi = {10.1111/jnc.15778}
}
EUVIMED